Allogene Therapeutics ALLO Lessee Operating Lease Liability Payments Due

Lessee Operating Lease Liability Payments Due at other companies

PrecigenPGEN

——

Immix Biopharma, Inc.IMMX

——

Artiva Biotherapeutics, Inc.ARTV

——

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's lessee operating lease liability payments due.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's lessee operating lease liability payments due?: Allogene Therapeutics (ALLO) reported lessee operating lease liability payments due of $102.69M in Q1 2026.
How has Allogene Therapeutics's lessee operating lease liability payments due changed year-over-year?: Allogene Therapeutics's lessee operating lease liability payments due decreased by 11.4% year-over-year, from $115.94M to $102.69M.